Madrigal Pharmaceuticals Inc (MDGL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $9.93B
Last updated: Nov 17, 2026 at 11:06 AM ET
Madrigal Pharmaceuticals Inc (MDGL) Earnings: Report Dates and Results
Madrigal Pharmaceuticals (MDGL) is expected to report earnings on Feb 17, 2027. In the quarter ended Sep 30, 2026, Madrigal Pharmaceuticals reported EPS of $1.83, above the -$1.09 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
MDGL has an expected report date of Feb 17, 2027.
MDGL Earnings Call
The latest MDGL earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, MDGL beat 21 and missed 19. Revenue for the quarter ended Sep 30, 2026 was $431.27M, up 50.1% from $287.27M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $1.83 | -$1.09 | -$1.38 - -$0.56 | +267.89% | Beat | N/A | 4 | 0 up, 0 down | Nov 3, 2026 | $431.27M |
| Jun 30, 2026 | -$1.99 | -$2.55 | N/A | +21.96% | Beat | N/A | 3 | 0 up, 1 down | Jul 30, 2026 | $364.25M |
| Mar 31, 2026 | -$1.38 | -$4.14 | -$4.48 - -$3.79 | +66.67% | Beat | N/A | 5 | 0 up, 2 down | May 6, 2026 | $311.34M |
| Dec 31, 2025 | -$2.57 | -$0.60 | -$4.42 - $1.36 | -325.57% | Miss | N/A | 7 | 0 up, 2 down | Feb 19, 2026 | $321.08M |
| Sep 30, 2025 | -$4.96 | -$1.99 | -$6.95 - -$0.66 | -149.25% | Miss | N/A | 14 | 2 up, 0 down | Nov 4, 2025 | $287.27M |
| Jun 30, 2025 | -$1.90 | -$3.53 | -$4.92 - -$2.25 | +46.18% | Beat | N/A | 13 | 2 up, 0 down | Aug 5, 2025 | $212.80M |
| Mar 31, 2025 | -$3.32 | -$3.79 | -$5.04 - -$2.71 | +12.40% | Beat | N/A | 13 | N/A | May 1, 2025 | $137.25M |
| Dec 31, 2024 | -$2.71 | -$4.12 | -$5.29 - -$3.44 | +34.30% | Beat | N/A | 14 | 4 up, 1 down | Feb 26, 2025 | $103.32M |
| Sep 30, 2024 | -$4.92 | -$6.91 | -$8.45 - -$6.28 | +28.80% | Beat | N/A | 15 | 4 up, 0 down | Oct 31, 2024 | $62.17M |
| Jun 30, 2024 | -$7.10 | -$7.66 | -$9.37 - -$6.52 | +7.31% | Beat | N/A | 15 | 1 up, 0 down | Aug 7, 2024 | $14.64M |
| Mar 31, 2024 | -$7.38 | -$6.28 | -$7.34 - -$4.86 | -17.52% | Miss | N/A | 13 | 0 up, 0 down | May 7, 2024 | N/A |
| Dec 31, 2023 | -$5.68 | -$5.34 | -$5.84 - -$4.58 | -6.37% | Miss | N/A | 12 | 0 up, 0 down | Feb 28, 2024 | $770000 |
| Sep 30, 2023 | -$5.34 | -$4.93 | -$5.74 - -$4.34 | -8.32% | Miss | N/A | 11 | 1 up, 0 down | Nov 6, 2023 | N/A |
| Jun 30, 2023 | -$4.69 | -$4.54 | -$5.08 - -$4.22 | -3.30% | Miss | N/A | 10 | 0 up, 0 down | Aug 8, 2023 | N/A |
| Mar 31, 2023 | -$4.23 | -$4.94 | -$5.73 - -$4.26 | +14.37% | Beat | N/A | 10 | 0 up, 0 down | May 9, 2023 | N/A |
| Dec 31, 2022 | -$4.98 | -$4.61 | -$5.13 - -$3.47 | -8.03% | Miss | N/A | 12 | 0 up, 0 down | Feb 23, 2023 | N/A |
| Sep 30, 2022 | -$4.75 | -$4.18 | -$4.60 - -$3.50 | -13.64% | Miss | N/A | 12 | 0 up, 0 down | Nov 3, 2022 | N/A |
| Jun 30, 2022 | -$4.14 | -$3.64 | N/A | -13.74% | Miss | N/A | N/A | 0 up, 0 down | Aug 4, 2022 | N/A |
| Mar 31, 2022 | -$3.36 | -$3.54 | -$4.18 - -$1.85 | +5.08% | Beat | N/A | 12 | 0 up, 0 down | May 9, 2022 | N/A |
| Dec 31, 2021 | -$3.78 | -$3.88 | -$4.19 - -$3.11 | +2.58% | Beat | N/A | 13 | N/A | Feb 24, 2022 | N/A |
| Sep 30, 2021 | -$3.79 | -$3.85 | -$4.08 - -$3.79 | +1.56% | Beat | N/A | 13 | N/A | Nov 4, 2021 | N/A |
| Jun 30, 2021 | -$3.72 | -$3.54 | -$3.92 - -$3.40 | -5.08% | Miss | N/A | 11 | N/A | Aug 5, 2021 | N/A |
| Mar 31, 2021 | -$3.32 | -$3.94 | -$4.42 - -$2.71 | +15.74% | Beat | N/A | 14 | N/A | May 6, 2021 | N/A |
| Dec 31, 2020 | -$3.82 | -$3.85 | -$4.25 - -$3.19 | +0.78% | Beat | N/A | 16 | N/A | Feb 25, 2021 | N/A |
| Sep 30, 2020 | -$3.75 | -$3.30 | -$4.12 - -$2.60 | -13.64% | Miss | N/A | 15 | N/A | Nov 5, 2020 | N/A |
| Jun 30, 2020 | -$3.18 | -$2.43 | -$2.53 - -$2.24 | -30.86% | Miss | N/A | 13 | N/A | Aug 6, 2020 | N/A |
| Mar 31, 2020 | -$2.34 | -$1.95 | -$2.03 - -$1.87 | -20.00% | Miss | N/A | 12 | N/A | May 7, 2020 | N/A |
| Dec 31, 2019 | -$1.80 | -$1.65 | -$2.51 - -$1.45 | -9.09% | Miss | N/A | 13 | N/A | Feb 26, 2020 | N/A |
| Sep 30, 2019 | -$1.39 | -$1.42 | -$2.44 - -$1.18 | +2.11% | Beat | N/A | 11 | N/A | Nov 6, 2019 | N/A |
| Jun 30, 2019 | -$1.28 | -$1.22 | -$1.78 - -$1.00 | -4.92% | Miss | N/A | 12 | N/A | Aug 7, 2019 | N/A |
| Mar 31, 2019 | -$0.98 | -$0.97 | -$1.34 - -$0.82 | -1.03% | Miss | N/A | 11 | N/A | May 8, 2019 | N/A |
| Dec 31, 2018 | -$0.75 | -$0.74 | -$1.07 - -$0.54 | -1.35% | Miss | N/A | 10 | N/A | Feb 27, 2019 | N/A |
| Sep 30, 2018 | -$0.56 | -$0.53 | -$0.79 - -$0.32 | -5.66% | Miss | N/A | 8 | N/A | Nov 6, 2018 | N/A |
| Jun 30, 2018 | -$0.45 | -$0.62 | -$1.17 - -$0.46 | +27.42% | Beat | N/A | 8 | N/A | Aug 7, 2018 | N/A |
| Mar 31, 2018 | -$0.45 | -$0.77 | -$1.14 - -$0.58 | +41.56% | Beat | N/A | 6 | N/A | May 8, 2018 | N/A |
| Dec 31, 2017 | -$0.67 | -$0.70 | -$0.89 - -$0.60 | +4.29% | Beat | N/A | 5 | N/A | Mar 13, 2018 | $250000 |
| Sep 30, 2017 | -$0.68 | -$0.79 | -$0.83 - -$0.69 | +13.92% | Beat | N/A | 2 | N/A | Nov 9, 2017 | N/A |
| Jun 30, 2017 | -$0.69 | -$0.60 | -$0.60 - -$0.60 | -15.00% | Miss | N/A | 1 | N/A | Aug 10, 2017 | N/A |
| Mar 31, 2017 | -$0.50 | -$0.87 | -$0.87 - -$0.87 | +42.53% | Beat | N/A | 1 | N/A | Apr 3, 2017 | N/A |
| Dec 31, 2016 | -$0.67 | -$1.39 | N/A | +51.80% | Beat | N/A | N/A | N/A | Mar 31, 2017 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$12.75, after -$22.11 the year before. It was -$4.71 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$12.75 | N/A |
| Dec 31, 2024 | -$22.11 | N/A |
| Dec 31, 2023 | -$19.94 | N/A |
| Dec 31, 2022 | -$17.23 | N/A |
| Dec 31, 2021 | -$14.61 | N/A |
| Dec 31, 2020 | -$13.09 | N/A |
| Dec 31, 2019 | -$5.45 | N/A |
| Dec 31, 2018 | -$2.21 | N/A |
| Dec 31, 2017 | -$2.54 | N/A |
| Dec 31, 2016 | -$4.71 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,100 words across 18 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 9,124 | 18 | |
| 2026Q2 | Jun 30, 2026 | 9,115 | 16 | |
| 2026Q1 | Mar 31, 2026 | 6,096 | 17 | |
| 2025Q4 | Dec 31, 2025 | 8,449 | 9 | |
| 2025Q3 | Sep 30, 2025 | 7,358 | 17 | |
| 2025Q2 | Jun 30, 2025 | 7,468 | 16 | |
| 2025Q1 | Mar 31, 2025 | 6,237 | 14 | |
| 2024Q4 | Dec 31, 2024 | 6,064 | 16 |
2026Q3 Earnings Call
Opening remarks
Tina Ventura Chief Investor Relations Officer Thanks. Good morning, everyone, and thank you for joining us to discuss Madrigal's third quarter 2026 results. We issued a press release this morning and posted a slide deck to accompany this webcast on the Investor Relations section of our website. On the call with me today are Bill Sibold, Chief Executive Officer, Dave Soergel, Chief Medical Officer, and Mardi Dier, Chief Financial Officer. They will provide prepared remarks, followed by Q&A. Please note that on slide two, we will be making certain forward-looking statements today. We refer you to our SEC filings for a discussion of the risks that may cause actual results to differ from the forward-looking statements. With that, I will now turn the call over to Bill on slide three.
Bill Sibold CEO Thanks, Tina, and thank you all for joining. The business is performing exceptionally well. Rezdiffra is growing rapidly, and the MASH market is accelerating. Rezdiffra's best-in-disease profile and our team's strong execution have established Rezdiffra as the foundational therapy in MASH. I'll summarize a few highlights. First, we delivered a $431 million quarter, crossed the $1 billion milestone in year-to-date net sales, and are now annualizing at more than $1.7 billion based on this quarter's results. We're continuing to steadily add patients and believe we're well on our way to mega-blockbuster status. Second, the U.S. F2/F3 MASH market is accelerating, on track to grow more than 30% this year. When you combine rapid market growth with Rezdiffra's patent protection expected into 2045, it's hard to find a more attractive growth opportunity in biotech. Third, we're advancing our F4c program with the same objective that has guided us in F2/F3: to be first and best. Our ongoing MAESTRO-NASH OUTCOMES trial positions us to deliver the first approved therapy for F4c. Our new MAESTRO-CSPH phase III trial is designed to be a practice-shaping trial that we expect to extend our competitive advantage and strengthen our long-term leadership. Let's move to our Q3 results, where I'll cover Rezdiffra and the expanding MASH market. Dave will discuss our pipeline progress, and Mardi will close with our financials. Turning to slide five, third quarter 2026 net sales were $431 million, up 50% year-over-year. This performance reflects growing demand for Rezdiffra and outstanding execution by our team. We built a broad and durable prescriber base early, and now we are driving depth. The positive experience our target specialists are having with Rezdiffra in the real world is translating into action. They are prescribing it more often. That growing depth, combined with excellent access, Rezdiffra's differentiated profile, and strong patient adherence, is why we continue to steadily add patients.
Frequently Asked Questions About MDGL
When is Madrigal Pharmaceuticals's next earnings date?
Madrigal Pharmaceuticals's next earnings report is expected for Feb 17, 2027.
Did MDGL beat earnings estimates last quarter?
Yes. Madrigal Pharmaceuticals reported EPS of $1.83 for the quarter ended Sep 30, 2026, above the -$1.09 estimate, a 267.89% surprise.
What EPS do analysts expect from MDGL next quarter?
The consensus EPS estimate for Madrigal Pharmaceuticals for the quarter ending Dec 31, 2026 is $1.14 from 20 analysts, with estimates from -$0.34 to $2.80.
How often does MDGL beat earnings estimates?
Madrigal Pharmaceuticals beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of -3.18%.
MDGL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts